U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the	Paperwork F	Reduction Act of 1995, no pers	ons are required to respond to a	collection of information unless it conta	ins a valid OMB contro	l number.		
	C	stitute for form 1449A/PTO		Complete if Known				
	Sut	Suitate for form 1448A/PTO		Application Number	10/649,873			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)				Filing Date	August 28, 2003			
				First Named Inventor	PELED Amnon et al			
				Group Art Unit				
				Examiner Name				
Sheet		2 O	f 3	Attorney Docket Number	26732	• •		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
Initials	No.1		publisher, city and/or c	, catalog, etc.) date, page(s), volume-issue number(s), country where published.				
	1	Baggiolini et al. "CC Chemokines in Allergic Inflammation", Immunology Today, 15(3): 127-133, 1994.						
	2	Cocchi et al. "Identit	Cocchi et al. "Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-					
			Suppressive Factors Produced by CD8+ T Cells", Science, 270: 1811-1815, 1995.					
	3			yelopoiesis, and Derailed Ce				
		Neuron Migration in	CXCR4- and SDF-1	-Deficient Mice" Proc. Natl	. Acad. Sci.			
		Neuron Migration in CXCR4- and SDF-1-Deficient Mice", Proc. Natl. Acad. Sci. USA, 95: 9448-9453, 1998.						
	4	Müller et al. "Involvement of Chemokine Receptors in Breast Cancer Metastasis",						
	,	Nature, 410: 50-56, 2001.						
	5	Strieter et al. "The Functional Role of the ELR Motif in CXC Chemokine-Mediated						
		Angiogenesis", The Journal of Biological Chemistry, 270(45): 27348-27357, 1995.						
	6	Vaddi et al. "Regulation of Monocyte Integrin Expression by β-Family						
		Chemokines", The Journal of Immunology, 153: 4721-4732, 1994.						
					,			
						-3-3-		

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

<sup>&</sup>lt;sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>&</sup>lt;sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>&</sup>lt;sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>&</sup>lt;sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

 $<sup>^{6}</sup>$  Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.